Key facts
- It has raised $100.0M across 3 recorded rounds; the latest was Later Stage VC (Series C) ($100.0M) in Apr 2023.
- 1 institutional filer reports fund marks on Boundless Bio across 6 filings.
- Boundless Bio has filed 3 Form Ds with the SEC since 2020, most recently Aug 2023 ($100.0M sold to 26 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Boundless Bio
Create free account
No card required
Funding rounds
3 roundsApr 2023Later Stage VC (Series C)$100.0M▮
About Boundless Bio
- Industry
- Drug Discovery
PA Mark — not yet priced
Boundless Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Boundless Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest Oct 20251 SEC-registered fund reported 6 fair-value marks on Boundless Bio between Apr 2025 and Oct 2025. Filer-level marks and implied $/share are available to Pro members.